Biopharma News
Scorpion Biological Services Opens San Antonio Biologics Facility
Scorpion’s new facility is designed for the development and manufacturing of clinical and commercial-scale biologic drugs.
Gerresheimer and Nelson Labs NV Announce E&L Partnership
Gerresheimer and Nelson Labs will work together to conduct extractables and leachables testing on upcoming primary packaging solutions.
Merck and Veeva Ink 10-Year Partnership Agreement
Under this deal, Merck, known as MSD outside of the United States and Canada, will select Veeva products for industry-specific software and data.
J&J to Acquire Abiomed for $16.6 Billion
Johnson & Johnson’s acquisition of Abiomed, a provider of heart pump technologies, is designed to bolster their position in the medical technology sector.
Lonza and Singzyme Enter Bioconjugates Partnership
Lonza and Singzyme will use Singzyme’s enzymatic conjugation platform to develop novel bioconjugates.
Purolite and Repligen Announce Ligand Partnership
Purolite and Repligen have extended their existing ligand partnership through 2032.
FDA Approves AstraZeneca’s Imjudo for Combination Liver Cancer Treatment
AstraZeneca’s Imjudo (tremelimumab) was approved by FDA in combination with Imfinzi (durvalumab) for treating unresectable liver cancer.
WHO Ranks South Africa’s Vaccine Regulatory System at a Functional Level of Maturity
South Africa’s vaccine regulator has reached new WHO level to ensure safety, quality, and effectiveness.
Aragen to Invest in New Formulation Manufacturing Facility in Hyderabad, India
Aragen’s new 12,000 ft² facility will include various dosage form capabilities, including oral solids, liquids, topicals, and films.
Recipharm to Add High-Speed Filling Line to Wasserburg Facility
Recipharm’s new high speed filling line, designed for pre-filled syringes and cartridges, is expected to be operational by May 2023.
Gilead and MacroGenics Enter $1.7 Billion Oncology Collaboration
Gilead and MacroGenics will work together on bispecific antibodies for the treatment of blood cancers.
Post-Transplant Lymphoproliferative Disease Treatment Receives Marketing Authorization Recommendation from EMA
Ebvallo (tabelecleucel) would be the first EMA-approved therapy for patients with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.
EMA Announces Positive Indication for Takeda’s Dengue Vaccine
Takeda’s dengue vaccine is designed to prevent disease caused by virus serotypes 1, 2, 3, and 4 in individuals four and older.
Merck and Moderna Enter $250 Million Cancer Vaccine Partnership
Merck has exercised a $250 million option with Moderna to jointly develop and commercialize cancer vaccine mRNA-4157/V940.
Alexion, AstraZeneca Acquire Genomic Medicines Company
Alexion’s acquisition of LogicBio is designed to accelerate the company’s growth in genomic medicines.
Amphista Therapeutics Enters Targeted Protein Degradation Partnership with Domainex
Amphista Therapeutics and Domainex will work together to develop treatments focusing on targeted protein degradation.
FDA Grants Fast Track Designation to Cue Biopharma
FDA has granted Fast Track designation for CUE-101, a treatment of recurrent/metastatic head and neck squamous cell carcinoma.
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Pfizer has completed its acquisition of Biohaven Pharmaceuticals for approximately $11.6 billion.
Citius Pharmaceuticals Announces Clinical Collaboration with the University of Pittsburgh
Citius and the University of Pittsburgh will investigate I/ONTAK in combination with pembrolizumab for treatment of recurrent or metastatic solid tumors.
Novo Nordisk and Octagon Therapeutics Enter Inflammatory Disease Research Collaboration
The collaboration will use Octagon’s functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise.
Alcami Adds Solid-State Characterization Capabilities to North Carolina Laboratory
The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.
Pfizer to Supply up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries
Pfizer is set to supply global fund up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID, for low-and-middle-income countries.
EC Approves Vabysmo for Two Leading Causes of Vision Loss
EC has approved Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss.
FDA Approves Bluebird Bio’s $3 Million CALD Treatment
FDA granted accelerated approval to Skysona (elivaldogene autotemcel), which is designed to slow the progression of neurologic dysfunction in adolescents with CALD.
Lonza Expands HPAPI Multipurpose Suite
Lonza has expanded its HPAPI multipurpose suite for payload-linker manufacturing.
Boehringer Ingelheim Adopts Virtuosi VR Education Platform
Boehringer Ingelheim will use Virtuosi to train employees at three aseptic sites across its network.
CytoReason Announces Expanded Collaboration Deal with Pfizer
CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.
Civica to Invest $27.8 Million in New Testing Facility
Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility.
Ensysce Biosciences and Quotient Sciences Announce Partnership
Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.
EMA Recommends Approval of Enjaymo
EMA has recommended approval of Enjaymo for the treatment of hemolytic anemia in adult patients with cold agglutinin disease.
